ghk-cu tolerance desensitization evidence GHK-Cu vs NAD+: Which Longevity Peptide Should You Take or Stack? Frontiers | Exploring the beneficial

While historically listed with an "unknown status," recent data releases in late 2025 and early 2026 have clarified the safety profile that helped justify the Category 1 reclassification. Study Design: A randomized, placebo-controlled, double-blind Phase 1 pilot study

Margonis et al

If you can help it, try not to schedule a vaccine spontaneously or at the last minute

There are currently ongoing observational studies and early-phase clinical investigations of BPC-157 in gastrointestinal disease, reflecting the strength of the gut healing literature and the relative accessibility of GI endpoints in human trials

Fatigue: Some researchers report tiredness in early days of use